Repros Therapeutics plans to sell common stock through public offering

Ladenburg Thalmann is underwriter; proceeds slated for clinical trials

By Devika Patel

Knoxville, Tenn., Dec. 19 - Repros Therapeutics Inc. will price a public sale of common stock, according to a Form S-1 filed Monday with the Securities and Exchange Commission.

Ladenburg Thalmann & Co. Inc. is the underwriter.

Proceeds will be used for general corporate purposes, including clinical trials for Androxal and Proellex.

Repros Therapeutics develops drugs for the treatment of reproductive disorders. The company is based in the Woodlands, Texas.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.